| Trial ID: | L4622 |
| Source ID: | NCT02650206
|
| Associated Drug: |
Victoza (Liraglutide) With Dietician Monitoring
|
| Title: |
Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2|Diabetes Mellitus, Type II|Diabetes Mellitus, Adult-Onset|Inflammation
|
| Interventions: |
DRUG: Victoza (liraglutide) with dietician monitoring|OTHER: Placebo with dietician monitoring
|
| Outcome Measures: |
Primary: Macrophage polarization: % M2 macrophages in adipose tissue and peripheral blood according to positivity for cell surface markers (measured by flow cytometry)., 30 months | Secondary: Inflammation, localized: Pro- and anti-inflammatory cytokines will be measured (IL6, IL-8, TNF-α, MCP-1, cell surface markers, and adiponectin) by rtPCR in adipose tissue and blood macrophages, 30 months|Inflammation, systemic: Plasma pro/anti-inflammatory cytokines: IL-6, hsCRP, cell surface markers, and adiponectin will be measured in plasma., 30 months|Macrophage polarization: M1 to M2 ratio in adipose tissue and peripheral blood according to cell surface markers (measured by flow cytometry), 30 months
|
| Sponsor/Collaborators: |
Sponsor: Stanford University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
56
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2015-01
|
| Completion Date: |
2019-09-27
|
| Results First Posted: |
|
| Last Update Posted: |
2020-06-09
|
| Locations: |
Freidenrich Center for Translational Research (FCTR), Stanford, California, 94305, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02650206
|
